Breaking News
Get 40% Off 0
Join +750K new investors every month who copy stock picks from billionaire's portfolios Sign Up Free
Close

Sino Biopharmaceutical Ltd (1177)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.75 -0.01    -0.36%
17:59:42 - Closed. Currency in HKD ( Disclaimer )
  • Volume: 32,948,795
  • Bid/Ask: 2.74 / 2.75
  • Day's Range: 2.71 - 2.79
Type:  Equity
Market:  Hong Kong
ISIN:  KYG8167W1380 
Sino Biopharmaceutical 2.75 -0.01 -0.36%

1177 Financial Summary

 
A brief financial summary of Sino Biopharmaceutical Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Sino Biopharmaceutical Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 26,199.41 million compared to CNY 26,026.16 million a year ago. Net income was CNY 2,331.94 million compared to CNY 2,543.57 million a year ago. Basic earnings per share from continuing operations was CNY 0.1021 compared to CNY 0.1131 a year ago. Diluted earnings per share from continuing operations was CNY 0.1021 compared to CNY 0.0986 a year ago. Basic earnings per share was CNY 0.1259 compared to CNY 0.1366 a year ago. Diluted earnings per share was CNY 0.1259 compared to CNY 0.1215 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

1177 Income Statement

Gross margin TTM 80.95%
Operating margin TTM 20.76%
Net Profit margin TTM 8.9%
Return on Investment TTM 9.09%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 7638.52 7638.52
Gross Profit 6010.27 6010.27
Operating Income 1562.68 1562.68
Net Income 629.39 629.39

1177 Balance Sheet

Quick Ratio MRQ 0.83
Current Ratio MRQ 1.05
LT Debt to Equity MRQ 3.53%
Total Debt to Equity MRQ 41.73%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 63604.82 63604.82 65640.89 65640.89
Total Liabilities 25434.87 25434.87 29182.08 29182.08
Total Equity 38169.95 38169.95 36458.8 36458.8

1177 Cash Flow Statement

Cash Flow/Share TTM 0.33
Revenue/Share TTM 1.42
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1335.56 1335.56
Cash From Investing Activities -2037.35 -2037.35
Cash From Financing Activities -2021.04 -2021.04
Net Change in Cash -2680.42 -2680.42
* In Millions of CNY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1177 Comments

Write your thoughts about Sino Biopharmaceutical Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email